Skip to main content

Table 1 Baseline characteristics between groups

From: Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study

Variable Erlotinib (n = 112) Gefitinib (n = 115) p - value
Age at onset (years) 58.4 ± 19.52 58.5 ± 20.13 0.212a
Sex    0.846b
 Female 85 86  
 Male 27 29  
Smoking status    0.644c
 Never a smoker 67 65  
 Former smokers 23 26  
 Current smokers 22 24  
Largest size of brain metastasis    0.841c
  ≤ 10 mm 26 28  
  > 10 mm 86 87  
Number of brain metastasis    0.764c
  ≤ 3 65 69  
  > 3 47 46  
ECOG performance status    0.838c
 0 33 35  
 1 46 43  
 2 25 27  
 3 8 10  
Neurological symptoms before the initiation of TKIs    0.352c
 Nausea 6 5  
 Headache 3 3  
 Depressed level of consciousness 2 2  
 Gait disturbance 1 0  
 Muscle weakness 0 1  
 Dizziness 1 1  
 Urinary retention 1 1  
 Cognitive disturbance 2 2  
 Memory impairment 1 2  
 Blurred vision 2 1  
  1. aAnalysed using independent-samples t-test. bAnalysed using chi-squared test. cAnalysed using the Mann-Whitney test. ECOG Eastern Cooperative Oncology Group. TKIs Tyrosine kinase inhibitors